Teva Pharmaceutical Industries Limited or Jazz Pharmaceuticals plc: Who Leads in Yearly Revenue?

Teva vs. Jazz: A Decade of Revenue Shifts

__timestampJazz Pharmaceuticals plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014117287500020272000000
Thursday, January 1, 2015132480300019652000000
Friday, January 1, 2016148797300021903000000
Sunday, January 1, 2017161869300022385000000
Monday, January 1, 2018189092200018854000000
Tuesday, January 1, 2019216176100016887000000
Wednesday, January 1, 2020236356700016658000000
Friday, January 1, 2021309423800015878000000
Saturday, January 1, 2022365937400014925000000
Sunday, January 1, 2023383420400015846000000
Monday, January 1, 202416544000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceuticals: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Jazz Pharmaceuticals plc have been key players. Over the past decade, Teva has consistently outpaced Jazz in terms of revenue, despite a noticeable decline. In 2014, Teva's revenue was nearly 17 times that of Jazz, but by 2023, this gap had narrowed to just over 4 times. Jazz Pharmaceuticals has shown impressive growth, with its revenue more than tripling from 2014 to 2023, reflecting a robust annual growth rate of approximately 15%. Meanwhile, Teva's revenue has seen a decline of about 22% over the same period. This shift highlights Jazz's strategic advancements and Teva's challenges in maintaining its market dominance. As the pharmaceutical industry evolves, these trends offer a glimpse into the dynamic shifts shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025